Boundless Bio Statistics

Total Valuation

Boundless Bio has a market cap or net worth of $32.33 million. The enterprise value is -$72.15 million.

Market Cap	32.33M
Enterprise Value	-72.15M

Important Dates

The next estimated earnings date is Monday, May 12, 2025, before market open.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Boundless Bio has 22.30 million shares outstanding. The number of shares has increased by 1,296.71% in one year.

Current Share Class	22.30M
Shares Outstanding	22.30M
Shares Change (YoY)	+1,296.71%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	1.75%
Owned by Institutions (%)	49.60%
Float	14.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.21
P/TBV Ratio	0.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 18.98, with a Debt / Equity ratio of 0.32.

Current Ratio	18.98
Quick Ratio	18.70
Debt / Equity	0.32
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -48.21% and return on invested capital (ROIC) is -28.53%.

Return on Equity (ROE)	-48.21%
Return on Assets (ROA)	-27.23%
Return on Invested Capital (ROIC)	-28.53%
Return on Capital Employed (ROCE)	-36.95%
Revenue Per Employee	n/a
Profits Per Employee	-$1.02M
Employee Count	64
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -87.54% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-87.54%
50-Day Moving Average	1.60
200-Day Moving Average	2.69
Relative Strength Index (RSI)	48.87
Average Volume (20 Days)	68,989

Short Selling Information

The latest short interest is 701,118, so 3.14% of the outstanding shares have been sold short.

Short Interest	701,118
Short Previous Month	722,349
Short % of Shares Out	3.14%
Short % of Float	4.94%
Short Ratio (days to cover)	10.74

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-73.27M
Pretax Income	n/a
Net Income	-65.36M
EBITDA	-72.18M
EBIT	-73.27M
Earnings Per Share (EPS)	-$3.85

Full Income Statement

Balance Sheet

The company has $152.11 million in cash and $47.63 million in debt, giving a net cash position of $104.48 million or $4.69 per share.

Cash & Cash Equivalents	152.11M
Total Debt	47.63M
Net Cash	104.48M
Net Cash Per Share	$4.69
Equity (Book Value)	150.64M
Book Value Per Share	6.76
Working Capital	146.26M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$60.84 million and capital expenditures -$2.54 million, giving a free cash flow of -$63.38 million.

Operating Cash Flow	-60.84M
Capital Expenditures	-2.54M
Free Cash Flow	-63.38M
FCF Per Share	-$2.84

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Boundless Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,296.71%
Shareholder Yield	-1,296.71%
Earnings Yield	-202.16%
FCF Yield	-196.01%

Analyst Forecast

The average price target for Boundless Bio is $22.50, which is 1,451.72% higher than the current price. The consensus rating is "Buy".

Price Target	$22.50
Price Target Difference	1,451.72%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2